11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets

11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets

Diabetes mellitus comprises a group of metabolic disorders characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. In cardiovascular secondary prevention, diabetes is not merely an isolated metabolic comorbidity; it represents a primary systemic vascular driver that interacts synergistically with hypertension, atherogenic dyslipidemia, and chronic inflammation to exacerbate cardiovascular disease (CVD).

---

Pathophysiological Divergence: Type 1 vs. Type 2 Diabetes Mellitus

Rehabilitation professionals must understand the distinct mechanistic origins and phenotypic differences between the two primary forms of diabetes, as these differences dictate pharmacotherapy, exercise metabolism, and acute safety protocols:

Type 1 Diabetes Mellitus: Autoimmune $\beta$-Cell Failure

Type 1 diabetes results from cell-mediated autoimmune destruction of insulin-secreting $\beta$-cells within the pancreatic islets of Langerhans. Activated CD4+ and CD8+ T-lymphocytes infiltrate the islets (insulitis), triggering progressive apoptosis. The clinical onset of symptomatic hyperglycemia typically occurs after 70% to 90% of functional $\beta$-cell mass is destroyed. Because endogenous insulin production ceases entirely, these individuals cannot suppress hepatic gluconeogenesis or lipolysis during fasting or exercise without exogenous insulin administration. Unregulated lipolysis floods the liver with free fatty acids, accelerating hepatic ketogenesis and predisposing to life-threatening Diabetic Ketoacidosis (DKA).

Type 2 Diabetes Mellitus: The Insulin Resistance & Secretory Continuum

Type 2 diabetes accounts for more than 90% of diabetic cases in cardiac rehabilitation. Pathophysiologically, it initiates with peripheral insulin resistance localized to skeletal muscle, adipose tissue, and hepatocytes:

1. Skeletal Muscle Resistance: Under normal conditions, skeletal muscle accounts for ~80% of postprandial insulin-stimulated glucose disposal. In T2D, post-receptor insulin signaling defects (impaired tyrosine phosphorylation of insulin receptor substrate-1 [IRS-1]) hinder the translocation of Glucose Transporter 4 (GLUT4) vesicles to the sarcolemma.
2. Hepatic Insulin Resistance: Insulin fails to downregulate hepatic glycogenolysis and gluconeogenesis, producing uninhibited fasting hepatic glucose output.
3. Adipose Tissue Lipotoxicity: Inability of insulin to suppress hormone-sensitive lipase leads to excessive lipolysis, elevating circulating free fatty acids (FFAs) that accumulate ectopically in the liver and myocardium, inducing lipotoxicity, mitochondrial oxidative stress, and impaired myocardial relaxation.
4. Pancreatic $\beta$-Cell Exhaustion: Initially, the pancreas mounts a compensatory hyperinsulinemic response to overcome peripheral resistance. Over years, genetic susceptibility, glucotoxicity, lipotoxicity, and amyloid deposition drive progressive $\beta$-cell secretory failure, precipitating overt hyperglycemia.

Type 2 diabetes is inextricably linked to Metabolic Syndrome, defined by the harmonized ATP III criteria (presence of $\ge 3$ of the following: waist circumference $\ge 102$ cm in men or $\ge 88$ cm in women; triglycerides $\ge 150$ mg/dL; HDL-C $<40$ mg/dL in men or $<50$ mg/dL in women; blood pressure $\ge 130/85$ mmHg or on antihypertensive therapy; fasting plasma glucose $\ge 100$ mg/dL or on antidiabetic therapy).

---

ADA Diagnostic Criteria and Prediabetes Classifications

The American Diabetes Association (ADA) establishes standardized laboratory criteria for screening, diagnosing, and stratifying diabetes and prediabetes. Diagnosing diabetes requires two abnormal test results from the same sample or two separate test samples, unless overt symptomatic hyperglycemia is present:

Clinical Nuances of Diagnostic Testing

• Fasting Plasma Glucose (FPG): Mandates a minimum 8-hour fast without caloric intake. It primarily reflects hepatic insulin resistance and uninhibited basal gluconeogenesis.
• 2-Hour Oral Glucose Tolerance Test (OGTT): Assesses glucose clearance 120 minutes following ingestion of a standardized 75-gram anhydrous glucose solution dissolved in water. It is the most sensitive test for identifying early postprandial glucose dysregulation and impaired peripheral skeletal muscle disposal.
• Glycated Hemoglobin ($HbA_{1c}$): Reflects the non-enzymatic glycation of the N-terminal valine of the hemoglobin $\beta$-chain, providing an integrated measure of average ambient glycemia over the preceding 8 to 12 weeks (the average erythrocyte lifespan of 120 days). Assays must be certified by the National Glycohemoglobin Standardization Program (NGSP). Conditions that accelerate red blood cell turnover (e.g., hemolytic anemia, chronic kidney disease on erythropoietin, recent acute blood loss or transfusion post-CABG) falsely depress $HbA_{1c}$, whereas iron-deficiency anemia or splenectomy falsely elevate it.
• Random Plasma Glucose: A value $\ge 200\text{ mg/dL}$ ($11.1\text{ mmol/L}$) in an individual exhibiting classic hyperglycemic symptoms (polyuria, polydipsia, polyphagia, unintentional weight loss) or hyperglycemic crisis confirms diabetes without requiring repeat testing.

---

Glycemic Targets in Secondary Prevention

In cardiac rehabilitation cohorts, optimizing glycemic control reduces microvascular complications and long-term cardiovascular events. However, the landmark ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial demonstrated that aggressive normalization of blood glucose (targeting $HbA_{1c} < 6.0\%$) using older multi-drug regimens increased all-cause mortality, primarily driven by severe, unheralded hypoglycemia in older adults with established vascular disease. Consequently, the ADA, ACC, and AHA mandate individualized glycemic targets:

 Stringent Target (<6.5%) ◄──────── Standard Secondary Prevention ────────► Relaxed Target (<8.0%)
   Younger, newly diagnosed                   HbA1c < 7.0%                     Frail, long-standing T2D,
   No established CVD/CKD             (Most Adults with Stable CAD)          Advanced CKD, HFrEF, high
   No hypoglycemia risk                                                      hypoglycemia vulnerability

ADA Glycemic Target Framework

1. Standard Target ($HbA_{1c} < 7.0\%$ / $< 53\text{ mmol/mol}$):
   • Recommended for the majority of non-pregnant adults with stable cardiovascular disease.
   • Corresponds to an Estimated Average Glucose (eAG) of approximately $154\text{ mg/dL}$ ($8.6\text{ mmol/L}$).
   • Preprandial capillary plasma glucose goal: $80\text{--}130\text{ mg/dL}$ ($4.4\text{--}7.2\text{ mmol/L}$).
   • Peak postprandial capillary plasma glucose goal (1–2 hours post-meal): $< 180\text{ mg/dL}$ ($< 10.0\text{ mmol/L}$).
2. Stringent Target ($HbA_{1c} < 6.5\%$ / $< 48\text{ mmol/mol}$):
   • Appropriate for selected younger individuals with short diabetes duration, long life expectancy, no significant cardiovascular comorbidities, and treated exclusively with lifestyle or agents with low hypoglycemia risk (e.g., metformin, SGLT2i, GLP-1 RA).
3. Less Stringent / Relaxed Target ($HbA_{1c} < 8.0\%$ / $< 64\text{ mmol/mol}$, or $<8.5\%$):
   • Mandatory for patients with a history of severe hypoglycemia, hypoglycemia unawareness, limited remaining life expectancy, advanced microvascular complications, end-stage renal disease, or severe heart failure (HFrEF).
   • In these individuals, the acute cardiovascular hazards of hypoglycemia (sympathoadrenal surge, fatal arrhythmias, myocardial ischemia) far outweigh the long-term microvascular benefits of tight control.
4. Continuous Glucose Monitoring (CGM) Metrics:
   • Time in Range (TIR, 70–180 mg/dL): Target $> 70\%$ of readings.
   • Time Below Range (TBR, <70 mg/dL): Target $< 4\%$ (and $<1\%$ for $<54\text{ mg/dL}$).

---

Vascular Complications: Microvascular vs. Macrovascular Pathophysiology

Chronic hyperglycemia exerts devastating structural effects on the vascular tree via distinct molecular cascades:

1. Microvascular Complications

Microvascular disease specifically damages small arterioles and capillaries in tissues where glucose uptake is insulin-independent (endothelium, retinal pericytes, renal mesangium, schwann cells):

• Molecular Mediators: Intracellular hyperglycemia overwhelms glycolysis, diverting excess glucose into:
  • Advanced Glycation End-Products (AGEs): Non-enzymatic glycation of extracellular matrix proteins induces cross-linking of vascular collagen, quenching nitric oxide (NO) and activating the RAGE receptor, promoting inflammatory cytokine release.
  • Protein Kinase C (PKC) Activation: Hyperglycemia stimulates de novo synthesis of diacylglycerol (DAG), activating PKC isoforms that upregulate vascular endothelial growth factor (VEGF) and endothelin-1, inducing capillary hyperpermeability and basement membrane thickening.
  • Polyol (Sorbitol) Pathway: Aldose reductase converts excess glucose to sorbitol, consuming NADPH. Depleted NADPH impairs glutathione reduction, inducing massive intracellular reactive oxygen species (ROS) accumulation.
• End-Organ Pathology:
  • Diabetic Retinopathy: Non-proliferative (microaneurysms, hemorrhages, hard exudates) progressing to proliferative retinopathy (ischemia-driven neovascularization, vitreous hemorrhage, tractional retinal detachment).
  • Diabetic Kidney Disease (Nephropathy): Glomerular hyperfiltration, mesangial expansion, nodular glomerulosclerosis (Kimmelstiel-Wilson lesions), and progressive albuminuria.
  • Diabetic Neuropathy: Distal sensorimotor polyneuropathy and cardiovascular autonomic neuropathy (CAN).

2. Macrovascular Complications & CAD Risk Equivalence

Macrovascular complications manifest as accelerated atherosclerosis across major arterial distributions: Coronary Artery Disease (CAD), Cerebrovascular Disease (stroke/TIA), and Peripheral Artery Disease (PAD).

• Atherogenic Milieu: Driven by insulin resistance rather than hyperglycemia alone. Characterized by endothelial dysfunction, reduced endothelial nitric oxide synthase (eNOS) activity, upregulation of vascular cell adhesion molecules (VCAM-1, ICAM-1), dense platelet hyperreactivity, and atherogenic dyslipidemia (elevated triglycerides, low HDL-C, and predominance of small, dense, highly oxidized LDL particles).
• Impaired Fibrinolysis: Patients with diabetes exhibit marked elevations in plasminogen activator inhibitor-1 (PAI-1) and fibrinogen, creating a prothrombotic state that retards spontaneous clot lysis following plaque rupture.
• CAD Risk Equivalence: In 1998, the landmark Finnish East West Study led by Haffner et al. established that patients with Type 2 diabetes without prior myocardial infarction had a 7-year risk of fatal or nonfatal MI (~20%) equivalent to non-diabetic individuals with a documented prior MI. This established diabetes as a CAD risk equivalent, mandating aggressive secondary prevention targets (statins, antiplatelet agents, ACEi/ARB, and blood pressure control) matching those for established coronary artery disease.

---

Realistic Clinical Scenario: Diagnostic Stratification and Glycemic Goal Setting

Clinical Scenario: A 63-year-old male with a history of hypertension, obesity (BMI $33.4\text{ kg/m}^2$, waist circumference 108 cm), and recently stented LAD following an acute non-ST-elevation myocardial infarction (NSTEMI) enrolls in Phase II cardiac rehabilitation. During intake assessment, his medical chart lists no prior history of diabetes. Routine baseline fasting laboratory analysis reveals:

• Fasting Plasma Glucose (FPG): $142\text{ mg/dL}$
• Glycated Hemoglobin ($HbA_{1c}$): $7.8\%$ ($62\text{ mmol/mol}$)
• Fasting Lipid Panel: Total Cholesterol $198\text{ mg/dL}$, Triglycerides $240\text{ mg/dL}$, HDL-C $34\text{ mg/dL}$, LDL-C $116\text{ mg/dL}$
• Blood Pressure: $138/86\text{ mmHg}$ on carvedilol and lisinopril

Clinical Assessment & Action Plan:

1. Diagnostic Confirmation: The patient meets the diagnostic threshold for overt Type 2 diabetes mellitus ($HbA_{1c} \ge 6.5\%$ and $\text{FPG} \ge 126\text{ mg/dL}$). He also satisfies ATP III criteria for Metabolic Syndrome (elevated waist circumference, hypertriglyceridemia, low HDL-C, hypertension, hyperglycemia).
2. Target Formulation: As a 63-year-old with newly diagnosed T2D and established coronary artery disease without prior hypoglycemia or advanced CKD, his target $HbA_{1c}$ is set at $< 7.0\%$ ($< 53\text{ mmol/mol}$).
3. Rehabilitation Strategy: The CR clinician collaborates with the medical director and primary endocrinologist to initiate guideline-directed antidiabetic pharmacotherapy with proven cardiovascular benefit (e.g., metformin plus SGLT2i or GLP-1 RA), educates the patient on exercise-induced glycemic changes, and initiates continuous telemetry monitoring.